Insulins- MPR

Insulins

INSULINS
Preparation	Brand		Route	Onset (mins)	Peak (hrs)	Duration (hrs)	Source
RAPID-ACTING
insulin	Afrezza¹	Rx	oral inh	12	0.5–1	1.5–4.5	human
insulin aspart	Fiasp²	Rx	SC, IV⁴, CSII	16–20	1.5–2	5–7	human
insulin aspart	Novolog²	Rx	SC, IV⁴, CSII	10−20	1–3	3−5	human
insulin glulisine	Apidra³	Rx	SC, IV⁴, CSII	≤15	1	2−4	human
insulin lispro	Admelog³	Rx	SC, IV⁴, CSII	≤15	2	<6	human
insulin lispro	Humalog³	Rx	SC, IV^4,5, CSII5	≤15	0.5−1.5	3−5	human
insulin lispro-aabc	Lyumjev³	Rx	SC, IV^4,5, CSII⁵	15–17	2–2.9	4.6–7.3	human
SHORT-ACTING
insulin regular	Humulin R U-100¹	OTC	SC, IV⁴	~30	~3	~8	human
	Humulin R U-500¹	Rx	SC	<15mins	4–8	21	human
	Novolin R²	OTC	SC, IV⁴	30	1.5–2.5	8	human
INTERMEDIATE-ACTING
insulin isophane suspension (NPH)	Humulin N¹	OTC	SC	60−120	6.5	18−24	human
insulin isophane suspension (NPH)	Novolin N²	OTC	SC	60–120	4–12	up to 24	human
SHORT- AND INTERMEDIATE-ACTING MIXTURES
insulin aspart protamine/ insulin aspart	Novolog Mix 70/30²	Rx	SC	10−20	1.8−3.6	up to 24	human
insulin isophane suspension (NPH)/ insulin regular	Humulin 70/30¹	OTC	SC	30–90	1.5–6.5	18−24	human
insulin isophane suspension (NPH)/ insulin regular	Novolin 70/30²	OTC	SC	30	2−12	up to 24	human
insulin lispro protamine/ insulin lispro	Humalog Mix 50/50³	Rx	SC	≤15	1−5	11–22	human
insulin lispro protamine/ insulin lispro	Humalog Mix 75/25³	Rx	SC	≤15	1−6	13−22	human
LONG-ACTING
insulin degludec	Tresiba³	Rx	SC	60	none	≥42	human
insulin detemir	Levemir³	Rx	SC	60	none	up to 24	human
insulin glargine	Basaglar³	Rx	SC	60	none	≥24	human
	Lantus³	Rx	SC	60	none	≥24	human
	Rezvoglar³	Rx	SC	60	none	≥24	human
	Semglee³	Rx	SC	varies	none	≥24	human
	Toujeo³	Rx	SC	360	none	up to 36	human
NOTES
Key: CSII = continuous subcutaneous insulin infusion; inh = inhalation; IV = intravenous infusion; SC = subcutaneous inj ¹ Recombinant (using E. coli) ² Recombinant (using S. cerevisiae) ³ Recombinant human insulin analogue ⁴ IV to be used in a clinical setting under proper medical supervision ⁵ IV and CSII administration for U-100 only. The time course of action of insulin and insulin analogs may vary considerably in different individuals or within the same individual. All times are approximate. The parameters of insulin activity (time of onset, peak time and duration) should be considered only as general guidelines. Onset for injectable formulations is always for the SC route. Injectable insulins listed are available in a concentration of 100Units/mL; Humulin R, in a concentration of 500Units/mL for SC injection only, is available by prescription from Lilly for insulin resistant patients who are hospitalized or under close medical supervision. Not an inclusive list of medications and/or dosing instructions. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. (Rev. 7/2023)

Want to read more?